Form 10-Q Neurogene Inc. For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Neurogene (NGNE) PT Lowered to $45 at BMO Capital
November 19, 2024 4:02 PM ESTBMO Capital analyst Keith Tapper lowered the price target on Neurogene (NASDAQ: NGNE) to $45.00 (from $60.00) while maintaining a Outperform rating.
The analyst comments "Neurogene shares are trading near cash on: 1) emerging SAE in a high-dose patient, consistent with overexposure/overdose of AAV9 or adenovirus... More
